Quality of colonoscopy in Lynch syndrome

Lynch syndrome (LS) accounts for 2 – 4 % of all colorectal cancers. Affected family members have a germline mutation in one of the DNA mismatch repair genes MLH1, PMS2, MSH2, or MSH6, and a lifetime risk for development of colorectal cancer of 25 – 75 %. Current guidelines recommend annual to biannual surveillance colonoscopy in mutation carriers. Several factors may predict failure to prevent interval cancer in LS: more lesions in the right colon; more flat (“non polypoid”) and lateral growing polyps; small adenomas may already harbor high grade dysplasia or a high percentage of villous component and become advanced adenomas; there is a short duration of the adenoma – carcinoma sequence; synchronous lesions have high prevalence; patients are younger and less tolerant to colonoscopy (need more sedation); and repeated colonoscopies are needed for lifelong surveillance (patient experience is important for compliance). In order to prevent cancer in LS patients, surveillance colonoscopy should be performed in an endoscopic unit experienced with LS, every 1 – 2 years, starting at age 20 – 25 years, or 10 years younger than the age of first diagnosis in the family (whichever is first), and yearly after the age of 40 years. Colonoscopy in LS patients should be a very meticulous and precise procedure (i. e. taking sufficient withdrawal time, documentation of such warranted), with removal of all of the polyps, special attention to the right colon and alertness to flat lesions. Following quality indicators such as successful cleansing of the colon and removal of every polyp will probably improve prevention of interval cancers. At this moment, none of the new endoscopic techniques have shown convincing superiority over conventional high resolution white light colonoscopy.

• References

• 1 Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-932
• 2 Aramio M, Sankila R, Pukalla E et al. Cancer risk in mutation carriers of DNA mismatch-repair genes. Int J Cancer 1999; 81: 214-218
• 3 Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995; 108: 1405-1411
• 4 Vasen HF, Abdirahman M, Brohet R et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 2010; 138: 2300-2306
• 5 Engel C, Rahner N, Schulman K et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary non polyposis colorectal cancer. Clin Gastroenterol Hepatol 2010; 8: 174-182
• 6 Stuckless S, Green JS, Morgenstern M et al. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. Clin Genet 2012; 82: 439-445
• 7 Jarvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-834
• 8 de Jong AE, Hendriks YM, Kleibeuker JH et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006; 130: 665-671
• 9 Haanstra JF, Vasen HF, Sanduleanu S et al. Quality colonoscopy and risk of interval cancer in Lynch syndrome. Int J Colorectal Dis 2013; 28: 1643-1649
• 10 de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen GE et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002; 45: 1588-1594
• 11 Mecklin JP, Aarnio M, Laara E et al. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 2007; 133: 1093-1098
• 12 de Vos tot Nederveen Cappel WH, Jarvinen HJ, Lynch PM et al. Colorectal surveillance in Lynch syndrome families. Fam Cancer 2013; 12: 261-265
• 13 Rondagh EJ, Gulikers S, Gomez-Garcia EB et al. Nonpolypoid colorectal neoplasms: a challenge in endoscopic surveillance of patients with Lynch syndrome. Endoscopy 2013; 45: 257-264
• 14 Lecomte T, Cellier C, Meatchi T et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol 2005; 3: 897-902
• 15 Hurlstone DP, Karajeh M, Cross SS et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective “back-to-back” endoscopic study. Am J Gastroenterol 2005; 100: 2167-2173
• 16 Huneburg R, Lammert F, Rabe C et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 2009; 41: 316-322
• 17 East JE, Suzuki N, Stavrinidis M et al. Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer. Gut 2008; 57: 65-70
• 18 Stoffel EM, Turgeon DK, Stockwell DH et al. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Can Prev Res 2008; 1: 470-475
• 19 Ramsoekh D, Haringsma J, Poley JW et al. A back-to-back comparison of white light video endoscopy with autofluorescence endoscopy for adenoma detection in high-risk subjects. Gut 2010; 59: 785-793
• 20 Kaminski MF, Regula J, Kraszewska E et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362: 1795-1803
• 21 Edelstein DL, Axilbund J, Baxter M et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol 2011; 9: 340-343
• 22 Lindor NM, Peterson GM, Hadley DW et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006; 296: 1507-1517
• 23 Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121: 198-213
• 24 Vasen HF, Moslen G, Alonso A et al. Guidelines for the clinical management of Lynch syndrome (Hereditary non-polyposis cancer). J Med Genet 2007; 44: 353-362
• 25 Vasen HF, Blanco I, Aktan-Collan K et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62: 812-823
• 26 National Comprehensive Cancer Network. Guidelines for detection, prevention, and risk reduction. Available from: http://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf Version 1.2013
• 27 Stoffel EM, Chittenden A. Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high-risk patients. Gastroenterology 2010; 139: 1436-1441
• 28 Stuckless S, Green JS, Morgenstern M et al. Impact of colonoscopic screening in male and female LS carriers with the MSH2 mutation. Clin Genet 2012; 82: 439-445
• 29 Aarnio M, Sankilla R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-218
• 30 Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005; 42: 491-496
• 31 Stoffel E, Mukherjee B, Raymond VM et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009; 137: 1621-1627
• 32 Diergaarde B, Braam H, Vasen HF et al. Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 2007; 5: 736-742